REEP2 inhibitors target various aspects of cellular function, particularly those related to the endoplasmic reticulum (ER) and calcium homeostasis, to achieve inhibition of REEP2. Inhibitors that affect calcium channels and release mechanisms exert their influence by altering the calcium balance within cells. By blocking calcium channels or antagonizing receptors that mediate calcium release from the ER, these inhibitors can modify the intracellular calcium levels, which are vital for numerous cellular processes. Given that REEP2 is associated with shaping and maintaining ER morphology, disruptions in calcium signaling can have profound effects on its function. Another approach to inhibiting REEP2 involves compounds that interfere with the cytoskeleton and vesicular transport systems. These compounds can destabilize the actin network or the microtubule assembly, both of which are integral to maintaining ER structure and hence REEP2 function. Alterations in ER-Golgi transport, induced by specific inhibitors, also impact the maintenance of ER network homeostasis, which is crucial for the functional role of REEP2.
Additionally, some inhibitors target enzymatic pathways that could affect the phosphorylation status of proteins, including REEP2. By inhibiting protein phosphatases, these compounds may induce changes in the phosphorylation state that are essential for the proper function of REEP2. Similarly, compounds that disrupt ion gradients across membranes or inhibit glycosylation processes can compromise the integrity and function of the ER, potentially impeding the role of REEP2 in ER morphogenesis. Moreover, compounds that affect protein folding and maturation through the inhibition of molecular chaperones can lead to a decrease in functional REEP2 levels.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
This calcium channel blocker directly inhibits the influx of calcium ions, which may impair the function of REEP2 involved in ER shaping and modulation of calcium-dependent cytosolic processes. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
Acts as a modulator of the IP3 receptor and inhibits calcium release from the endoplasmic reticulum, potentially affecting REEP2's role in ER tubule formation and maintenance. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
This ryanodine receptor antagonist inhibits calcium release from the sarcoplasmic/endoplasmic reticulum, which could indirectly decrease REEP2 activity if it relies on calcium signaling for its function. | ||||||
Fostriecin | 87860-39-7 | sc-202160 | 50 µg | $260.00 | 9 | |
A potent inhibitor of protein phosphatase 2A (PP2A), which could alter phosphorylation states of proteins including REEP2, potentially leading to its functional inhibition if phosphorylation is critical for its activity. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
As an ionophore that disrupts sodium and hydrogen ion gradients across membranes, it could interfere with the ER membrane's integrity, indirectly inhibiting REEP2's role in ER morphology. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Disrupts ER-Golgi transport by inhibiting ADP-ribosylation factor, which could indirectly affect REEP2's role in ER network maintenance through altered trafficking dynamics. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
As a SERCA pump inhibitor, it prevents calcium sequestration into the ER, possibly impacting REEP2's function if it is calcium-dependent. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
An N-linked glycosylation inhibitor, which can disrupt ER function and potentially affect REEP2's role in ER morphogenesis. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Inhibits actin polymerization, potentially affecting cytoskeletal interactions with the ER and consequently REEP2's function in maintaining ER structure. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Disrupts microtubule polymerization and could impair ER morphology and distribution, thereby indirectly inhibiting the function of REEP2 associated with microtubules. | ||||||